(RSS) (BioRxiv All) Serum proteomics reveals distinct phenotypic signatures to IL-6 blockade between two immunotherapies: A recent clinical study tested the effects of two different monoclonal antibodies (mAbs) (siltuximab, anti-IL6; tocilizumab, anti-IL6R) on the fate and function of T-cells in people with type 1 diabetes. While both mAbs affect the response of T-cells to stimulation, they have very different, sometimes opposing mechanisms. Here,… https://www.biorxiv.org/content/10.64898/2026.03.27.712461v1?rss=1&utm_source=dlvr.it&utm_medium=mastodon #BioRxiv #MassSpecRSS